To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Long noncoding RNAs and n… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Long noncoding RNAs and neuroblastoma.

Review article
Authors Gaurav Kumar Pandey
Chandrasekhar Kanduri
Published in OncoTarget
Volume 6
Issue 21
Pages 18265-75
ISSN 1949-2553
Publication year 2015
Published at Institute of Biomedicine, Department of Medical and Clinical Genetics
Pages 18265-75
Language en
Keywords MYCN; NBAT1; neuroblastoma; neuronal differentiation; noncoding RNA
Subject categories Biological Sciences, Basic Medicine, Health Sciences, Medical Biotechnology


Neuroblastoma is a disease that affects infants and despite intense multimodal therapy, high-risk patients have low survival rates (<50%). In recent years long noncoding RNAs (lncRNAs) have become the cutting edge of cancer research with inroads made in understanding their roles in multiple cancer types, including prostate and breast cancers. The roles of lncRNAs in neuroblastoma have just begun to be elucidated. This review summarises where we are with regards to lncRNAs in neuroblastoma. The known mechanistic roles of lncRNAs during neuroblastoma pathogenesis are discussed, as well as the relationship between lncRNA expression and the differentiation capacity of neuroblastoma cells. We speculate about the use of some of these lncRNAs, such as those mapping to the 6p22 hotspot, as biomarkers for neuroblastoma prognosis and treatment. This novel way of thinking about both neuroblastoma and lncRNAs brings a new perspective to the prognosis and treatment of high-risk patients.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?